Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis

BACKGROUND: Despite advancements in checkpoint inhibitor-based immunotherapy, patients with advanced melanoma who have progressed on standard dose ipilimumab (Ipi) + nivolumab continue to have poor prognosis. Several studies support a dose-response activity of Ipi, and one promising combination is I...

Descripción completa

Detalles Bibliográficos
Autores principales: Williamson, Julie, Fadlullah, Muhammad Zaki Hidayatullah, Kovacsovics-Bankowski, Magdalena, Gibson, Berit, Swami, Umang, Erickson-Wayman, Alyssa, Jamison, Debra, Sageser, Dan, Jeter, Joanne, Bowles, Tawnya, Cannon, Donald M., Haaland, Ben, Schroeder, Joyce D, Nix, David, Atkinson, Aaron, Hyngstrom, John, McPherson, Jordan, Tan, Aik-Choon, Hu-Lieskovan, Siwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312907/
https://www.ncbi.nlm.nih.gov/pubmed/37398360
http://dx.doi.org/10.21203/rs.3.rs-2997157/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312907/
https://www.ncbi.nlm.nih.gov/pubmed/37398360
http://dx.doi.org/10.21203/rs.3.rs-2997157/v1

Ejemplares similares